Biomarkers and the prediction of adverse outcomes in patients with acute decompensated heart failure and kidney injury
https://doi.org/10.17802/2306-1278-2021-10-3-65-71
Abstract
Abstract. Chronic heart failure is one of the main contributors to the Global Burden of Cardiovascular Diseases. Despite advances in modern treatment, acute decompensated heart failure (ADHF) incidence is high. Moreover, patients admitted for ADHF encounter renal impairment, which is another predictor of adverse outcome. There are number of biomarkers that allow clinicians to assess the prognosis of the disease in the early stages. The article presents an overview of contemporary biomarkers (utilizing multimarker approach), and identifies the most significant biological markers for evaluating ADHF and worsening renal function.
About the Authors
S. L. Glizer
Federal State Budgetary Educational Institution of Higher Education Krasnoyarsk State Medical University named after Prof. VF.Voino-Yasenetsky
Russian Federation
Competing Interests:
Russian Federation
Glizer Sofia L., postgraduate student, Department of Hospital Therapy and Family Medicine.
1, P Zheleznyaka St., Krasnoyarsk, 660022
Competing Interests:
С.Л. Глизер заявляет об отсутствии конфликтов интересов
O. A. Shtegman
Federal State Budgetary Educational Institution of Higher Education Krasnoyarsk State Medical University named after Prof. VF.Voino-Yasenetsky
Russian Federation
Competing Interests:
Russian Federation
Shtegman Oleg A., PhD, professor, Head of Department of Mobilization Training in Healthcare, Disaster Medicine, Emergency Medical Services.
1, P Zheleznyaka St., Krasnoyarsk, 660022
Competing Interests:
О.А. Штегман заявляет об отсутствии конфликтов интересов
M. M. Petrova
Federal State Budgetary Educational Institution of Higher Education Krasnoyarsk State Medical University named after Prof. VF.Voino-Yasenetsky
Russian Federation
Competing Interests:
Russian Federation
Petrova Marina M., PhD, professor, Head of Department of Hospital Therapy and Family Medicine.
1, P Zheleznyaka St., Krasnoyarsk, 660022
Competing Interests:
М.М. Петрова заявляет об отсутствии конфликтов интересов
References
1. Orso F., Fabbri G., Maggioni P Epidemiology of Heart Failure. Handp Exp Farmacol. 2017; 243: 15-33. doi: 10.1007/164_2016_74.
2. Zarudskij A.A., Sheljakina E.V., Shkileva I.Ju., Peruckaja E.A., Peruckij D.N. Epidemiology of systolic heart failure of systolicheart failure in our days. Health and Education Millennium. 2017; 19 (12): 167-171. (In Russian.)] http://dx.doi.org/10.26787/nydha-2226-7425-2017-19-12-167-171
3. Schefold J., Filippatos G., Hasenfuss G., Anker S., Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nature Reviews Nephrology. 2016; 12: 610-623. https://doi.org/10.1038/nrneph.2016.113
4. Piccinni P., Cruz D.N., Gramaticopolo S., Garzotto F., Dal Santo M., Aneloni G., Rocco M., Alessandri E., Giunta F., Michetti V, Iannuzzi M., Belluomo Anello C., Brienza N., Carlini M., Pelaia P, Gabbanelli V, Ronco C.; NEFROINT Investigators. et. al. Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol. 2011; 77(11): 1072-83.
5. Núñez J., Garcia S., Núñez E., Bonanad C., Bodí V., Miñana G., Santas E., Escribano D., Bayes-Genis A., PascualFigal D., Chorro F.J., Sanchis J. Early serum creatinine changes and outcomes in patients admitted for acute heart failure: the cardio-renal syndrome revisited. European Heart Journal. Acute Cardiovascular Care. 2017; 6 (5): 430-440. https://doi.org/10.1177/2048872614540094
6. Doshi R., Dhawan T., Rendon C., Rodriguez MA., Al-Khafaji JF., Taha M., Win T.T., Gullapalli N. Incidence and implications of acute kidney injury in patients hospitalized with acute decompensated heart failure. Intern Emerg Med. 2020; 15(3): 421-428. doi: 10.1007/s11739-019-02188-z.
7. Odutayo A., Wong C.X., Farkouh M., Altman D.G., Hopewell S., Emdin C.A., Hunn B.H. AKI and Long-Term Risk for Cardiovascular Events and Mortality. J Am Soc Nephrol. 2017; 28 (1): 377-387. doi: 10.1681/ASN.2016010105.
8. Nasonova S.N., Zhirov I.V., Ledyakhova M.V., Sharf T. V., Bosykh E.G., Masenko V.P., Tereshchenko S.N. Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure. Therapeutic Archive. 2019; 91 (4): 67-73. (In Russian.) doi: 10.26442/00403660.2019.04.000168
9. Ronco C., Bellasi A., Di Lullo L. Cardiorenal Syndrome: An Overview. Adv Chronic Kidney Dis. 2018; 25 (5): 382-390. doi: 10.1053/j.ackd.2018.08.004.
10. Reznik E.V, Nikitin I.G. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiology. The Russian Archives of Internal Medicine. 2019;9(1):5-22. (In Russian) doi: 10.20514/2226-6704-2019-9-1-5-22.
11. Kop’yeva K.V., Grakova E.V, Teplyakov A.T. New biomarkers of heart failure: NEW BIOMARKERS OF HEART diagnostic and prognostic value of NT-proBNP and interleukin receptor family members ST2. Complex Issues of Cardiovascular Diseases. 2018;7(1):94-101. (In Russian) doi: 10.17802/2306-1278-2018-7-1-94-101
12. Chow S.L., Maisel A.S., Anand I., Bozkurt B., de Boer R. A., Felker G.M., Fonarow G.C., Greenberg B., Januzzi J.L. Jr, Kiernan M.S., Liu P.P., Wang T.J., Yancy C.W., Zile M.R.; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017; 135 (22): e1054-e1091. doi: 10.1161/CIR.0000000000000490.
13. Braunwald E. Biomarkers in Heart Failure. The New England Journal of Medicine. 2008; 358: 2148-2159. doi: 10.1056/NEJMra0800239
14. Teplyakov, A.T., Grakova E.V., Berezikova E.N., Shilov S. N., Kop‘yeva K.V., Kaliuzhin V.K. Early markers of progression of Heart Failure and apoptosis: their role in predicting the risk of adverse cardiovascular events in patients with prior myocardial infarction. Bulletin of Siberian Medicine. 2016; 15 (1): 37-46. (In Russian) doi: 10.20538/1682-0363-2016-1-37-46.
15. Abdullaeb T.A., Mashhurova E. The value of the new ST 2 biomarker in patients with chronic heart failure. Eurasian Journal of Cardiology. 2019; (2S): 251. (In Russian)
16. Grakova E.V., T eplyakov A.T., Kopieva K.V., Akhmedov S. D., Ogurkova O.N., Soldatenko M.V. Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization. Cardiovascular Therapy and Prevention. 2018;17(5):40-46. (In Russian) doi: 10.15829/1728-8800-2018-5-40-46
17. Skvortsov A.A., Narusov O.Yu., Muksinova M.D., Protasov V.N., Protasova D.E., Kuznetsova T.V., Masenko V.P 1, Tereshchenko S.N. Clinical significance of serial biomarkers activity determination after acute heart failure decompensation: sST2 NT-proBNP role during long-term follow-up. Kardiologiia. 2018; 58 (12S): 27-41. (In Russian) doi:10.18087/cardio.2634
18. Peng Z., Xiaomei W., Guangxiao L., Hao S., Jingpu S. Prognostic role of copeptin with all-cause mortality after heart failure: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management. 2017; 13:49-58. doi https://doi.org/10.2147/TCRM.S124689
19. Protasov V.N., Narusov O.Yu., Skvortsov A.A., Protasova D.E., Kuznetsova T.V., Petrukhina A.A., Masenko V.P., Tereshchenko S.N. Multimarker Approach in Risk Stratification of Patients with Decompensated Heart Failure. Kardiologiia. 2019; 59(1S): 53-64. (In Russian) doi:10.18087/cardio.2637
20. House AA., Wanner C., Sarnak MJ., Pina IL., McIntyre CW., Komenda P., Kasiske B.L., Deswal A., deFilippi C.R., Cleland J.G.F., Anker S.D., Herzog C.A., Cheung M., Wheeler D.C., Winkelmayer W.C., McCullough PA.; Conference Participants. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95(6): 1304-1317. doi: 10.1016/j.kint.2019.02.022
21. Nasybullina A.A., Bulashova O.V., Gazizyanova V.M., Malkova M.I. Mustafin E.E., Husnutdinova G.R.. Markers of inflammation in patients with heart failure in association with chronic kidney disease // Kazan medical journal. 2016; 97 (6): 881-887. (In Russian) doi:10.17750/KMJ2016-881
22. Shyam R., Patel M.L., Sachan R., Kumar S., Pushkar D.K. Role of Urinary Neutrophil Gelatinase-associated Lipocalin as a Biomarker of Acute Kidney Injury in Patients with Circulatory Shock. Indian Journal of Critical Care Medicine. 2017; 21(11): 740-5. doi:10.4103/ijccm.IJCCM_315_17
23. Dankova M., Minarikova Z., Danko J., Gergel J., Pontuch P., Goncalvesova E. Novel biomarkers for prediction of acute kidney injury in acute heart failure. Bratisl Lek Listy. 2020; 121(5): 321-324. doi: 10.4149/BLL_2020_050
24. Lediakhova M. V., Zhirov I. V, Nasonova S. N., Uskach T. M., Masenko V P., Tereshchenko S. N. Acute kidney injury in acute decompensated heart failure: possibility of early diagnosis. Emergency Cardiology. 2018; 4:3-13. (In Russian.) doi: 10.25679/EMERGCARDIOLOGY2019.82.12.001
Review
For citations:
Glizer S.L., Shtegman O.A., Petrova M.M. Biomarkers and the prediction of adverse outcomes in patients with acute decompensated heart failure and kidney injury. Complex Issues of Cardiovascular Diseases. 2021;10(3):65-71. (In Russ.) https://doi.org/10.17802/2306-1278-2021-10-3-65-71
Views:
424
